TrialThe Lancet. Haematology2020

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Jean-Jacques Kiladjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.